Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q3 2019 · 10-Q
Revenue$311.80M$311.80M+79.5% vs Q3 2018 Net Income$43.20M$43.20M+106.7% vs Q3 2018 EPS Diluted$0.83$0.83+102.4% vs Q3 2018 Gross Profit$70,700,000+231.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flowderived-$3,100,000N/M Free Cash Flowderived-$18,400,000N/M Margins · derivedGross margin22.7%+10.4 pt vs Q3 2018
Operating margin22.7%+10.4 pt vs Q3 2018
Net margin13.9%+1.8 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 7, 2019 · 38 d after period end